Clinical Trial Update: Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer [NA]

View source ↗

Summary

A recruiting clinical trial evaluating adding pemetrexed to a third-generation EGFR tyrosine kinase inhibitor (e.g., osimertinib) versus the TKI alone for lepto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Guangzhou Medical University | Conditions: Leptomeningeal Metastasis | NA | Status: RECRUITING